Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

An adsorbent monolith device to augment the removal of uraemic toxins during haemodialysis.

Sandeman SR, Howell CA, Phillips GJ, Zheng Y, Standen G, Pletzenauer R, Davenport A, Basnayake K, Boyd O, Holt S, Mikhalovsky SV.

J Mater Sci Mater Med. 2014 Jun;25(6):1589-97. doi: 10.1007/s10856-014-5173-9. Epub 2014 Feb 27.

2.

Removal of protein-bound uraemic toxins by haemodialysis.

Niwa T.

Blood Purif. 2013;35 Suppl 2:20-5. doi: 10.1159/000350843. Epub 2013 May 3. Review.

PMID:
23676831
3.

Removal of protein-bound, hydrophobic uremic toxins by a combined fractionated plasma separation and adsorption technique.

Brettschneider F, Tölle M, von der Giet M, Passlick-Deetjen J, Steppan S, Peter M, Jankowski V, Krause A, Kühne S, Zidek W, Jankowski J.

Artif Organs. 2013 Apr;37(4):409-16. doi: 10.1111/j.1525-1594.2012.01570.x. Epub 2013 Jan 18.

PMID:
23330821
4.

Protein-bound uraemic toxin removal in haemodialysis and post-dilution haemodiafiltration.

Krieter DH, Hackl A, Rodriguez A, Chenine L, Moragues HL, Lemke HD, Wanner C, Canaud B.

Nephrol Dial Transplant. 2010 Jan;25(1):212-8. doi: 10.1093/ndt/gfp437. Epub 2009 Sep 15.

PMID:
19755476
5.

Effects of AST-120 on blood concentrations of protein-bound uremic toxins and biomarkers of cardiovascular risk in chronic dialysis patients.

Lee CT, Hsu CY, Tain YL, Ng HY, Cheng BC, Yang CC, Wu CH, Chiou TT, Lee YT, Liao SC.

Blood Purif. 2014;37(1):76-83. doi: 10.1159/000357641. Epub 2014 Feb 22.

PMID:
24576840
6.

Continuous Reduction of Protein-Bound Uraemic Toxins with Improved Oxidative Stress by Using the Oral Charcoal Adsorbent AST-120 in Haemodialysis Patients.

Yamamoto S, Kazama JJ, Omori K, Matsuo K, Takahashi Y, Kawamura K, Matsuto T, Watanabe H, Maruyama T, Narita I.

Sci Rep. 2015 Sep 23;5:14381. doi: 10.1038/srep14381.

7.

A haemocompatible and scalable nanoporous adsorbent monolith synthesised using a novel lignin binder route to augment the adsorption of poorly removed uraemic toxins in haemodialysis.

Sandeman SR, Zheng Y, Ingavle GC, Howell CA, Mikhalovsky SV, Basnayake K, Boyd O, Davenport A, Beaton N, Davies N.

Biomed Mater. 2017 May 10;12(3):035001. doi: 10.1088/1748-605X/aa6546.

PMID:
28270638
8.

Release of uremic retention solutes from protein binding by hypertonic predilution hemodiafiltration.

Böhringer F, Jankowski V, Gajjala PR, Zidek W, Jankowski J.

ASAIO J. 2015 Jan-Feb;61(1):55-60. doi: 10.1097/MAT.0000000000000166.

PMID:
25419832
9.

Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane.

Lesaffer G, De Smet R, Lameire N, Dhondt A, Duym P, Vanholder R.

Nephrol Dial Transplant. 2000 Jan;15(1):50-7.

PMID:
10607767
10.

p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease.

Wu IW, Hsu KH, Lee CC, Sun CY, Hsu HJ, Tsai CJ, Tzen CY, Wang YC, Lin CY, Wu MS.

Nephrol Dial Transplant. 2011 Mar;26(3):938-47. doi: 10.1093/ndt/gfq580. Epub 2010 Sep 29.

11.

Mixed matrix hollow fiber membranes for removal of protein-bound toxins from human plasma.

Tijink MS, Wester M, Glorieux G, Gerritsen KG, Sun J, Swart PC, Borneman Z, Wessling M, Vanholder R, Joles JA, Stamatialis D.

Biomaterials. 2013 Oct;34(32):7819-28. doi: 10.1016/j.biomaterials.2013.07.008. Epub 2013 Jul 19.

PMID:
23876759
12.

Uraemic toxins and cardiovascular disease across the chronic kidney disease spectrum: an observational study.

Rossi M, Campbell K, Johnson D, Stanton T, Pascoe E, Hawley C, Dimeski G, McWhinney B, Ungerer J, Isbel N.

Nutr Metab Cardiovasc Dis. 2014 Sep;24(9):1035-42. doi: 10.1016/j.numecd.2014.04.006. Epub 2014 May 4.

PMID:
24880738
13.

Why do patients on peritoneal dialysis have low blood levels of protein-bound solutes?

Vanholder R, Meert N, Van Biesen W, Meyer T, Hostetter T, Dhondt A, Eloot S.

Nat Clin Pract Nephrol. 2009 Mar;5(3):130-1. doi: 10.1038/ncpneph1023. Epub 2008 Dec 23. No abstract available.

PMID:
19107105
14.

Safety issues related to fractionated plasma separation, adsorption, and dialysis.

Meijers B, Evenepoel P.

Artif Organs. 2013 Aug;37(8):743-4. doi: 10.1111/aor.12119. Epub 2013 Jul 4. No abstract available.

PMID:
23826769
15.

Meta-Analysis of the Associations of p-Cresyl Sulfate (PCS) and Indoxyl Sulfate (IS) with Cardiovascular Events and All-Cause Mortality in Patients with Chronic Renal Failure.

Lin CJ, Wu V, Wu PC, Wu CJ.

PLoS One. 2015 Jul 14;10(7):e0132589. doi: 10.1371/journal.pone.0132589. eCollection 2015. Review.

16.

Exploring Protein Binding of Uremic Toxins in Patients with Different Stages of Chronic Kidney Disease and during Hemodialysis.

Deltombe O, Van Biesen W, Glorieux G, Massy Z, Dhondt A, Eloot S.

Toxins (Basel). 2015 Sep 28;7(10):3933-46. doi: 10.3390/toxins7103933.

17.

The removal of protein-bound solutes by dialysis.

Meyer TW.

J Ren Nutr. 2012 Jan;22(1):203-6. doi: 10.1053/j.jrn.2011.10.011. Review.

PMID:
22200443
18.

p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin.

Meijers BK, De Preter V, Verbeke K, Vanrenterghem Y, Evenepoel P.

Nephrol Dial Transplant. 2010 Jan;25(1):219-24. doi: 10.1093/ndt/gfp414. Epub 2009 Aug 19.

PMID:
19692415
19.

Vascular incompetence in dialysis patients--protein-bound uremic toxins and endothelial dysfunction.

Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Brunet P.

Semin Dial. 2011 May-Jun;24(3):327-37. doi: 10.1111/j.1525-139X.2011.00925.x. Review.

PMID:
21682773
20.

Serum protein-bound uraemic toxins and clinical outcomes in haemodialysis patients.

Lin CJ, Wu CJ, Pan CF, Chen YC, Sun FJ, Chen HH.

Nephrol Dial Transplant. 2010 Nov;25(11):3693-700. doi: 10.1093/ndt/gfq251. Epub 2010 May 13.

PMID:
20466687

Supplemental Content

Support Center